Civil Rights
Movements, leaders, victories and the continuing fight for equality.
q2K BHP
Black History Portal
THE BHP WIRE —
HIDDEN TRUTHS
What's New!
Explore the people, places, events, achievements, struggles and stories that shaped our journey.
Movements, leaders, victories and the continuing fight for equality.
Innovation, patents, science, technology and world-changing contributions.
Pioneers, champions, Negro Leagues, records, activism and excellence.
Meet the people whose lives, choices and achievements shaped the journey.
Black towns, communities, institutions and places where history happened.
Moments that changed communities, movements, institutions and the nation.
In 1968 Shirley Chisholm became the first Black woman elected to the United States Congress. In 1972 she launched a campaign for the Democratic presidential nomination, breaking another political barrier.
MORE →Reflects the personal views, recollections, and perspective of the author, Mike Davis.
This is a personal recollection on the Move fire on May 13, 1985
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Copenhagen Stock Exchange in Denmark, with American depositary receipts traded on the NASDAQ in the US.
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab. The most common side effects for ofatumumab (Kesimpta) include upper respiratory tract infection, headache, injection-related reactions, neutropenia, and local injection site reactions.
Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab. Daratumumab was granted breakthrough therapy drug status in 2013, for multiple myeloma. It was granted orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. It is available in combination with hyaluronidase as daratumumab/hyaluronidase (brand name Darzalex Faspro).
Donald Lee Drakeman is an American entrepreneur, venture capitalist, business executive, academic, and scholar based in South Carolina. He has since 2007 been a venture partner in Advent Venture Partners, a venture capital firm based in London, in connection with which he is a member of the firm's life sciences Team. At the same time he is a Distinguished Research Professor in the Center for Citizenship and Constitutional Government at the University of Notre Dame as well as a Fellow in Health Management of the Judge Business School at Cambridge University, where he is a member of the Operations and Technology Management Subject Group and associated with the Cambridge Centre for Health Leadership & Enterprise. He is in addition the Chairman of the advisory council of the James Madison Program in American Ideals and Institutions at Princeton University, where he was for many years a member of the faculty and taught lecture courses and seminars on civil liberties and the United States Constitution. His book Church, State, and Original Intent, which concerns the Establishment Clause of the First Amendment to the United States Constitution, was published by Cambridge University Press in 2010. In 2015 Palgrave Macmillan published Why We Need the Humanities, which focuses on the relation of the humanities to the life sciences and to civil liberties. In 2021 Cambridge University Press published The Hollow Core of Constitutional Theory: Why We Need the Framers, which defends the idea that the intentions of the Framers ought to have a central role in constitutional interpretation. He is also one of the authors of From Breakthrough to Blockbuster: The Business of Biotechnology, which was published in 2022 by Oxford University Press. He was educated at Dartmouth College (AB magna cum laude), Columbia Law School (JD Harlan Fiske Stone Scholar), and Princeton University (MA, PhD in Religion). A resident of Montclair, New Jersey, he was appointed in 1994 as chair of the township's zoning board of adjustment. In the early stages of his career he worked as an attorney at Milbank, Tweed, Hadley & McCloy and was the vice-president of the Essex Chemical Corporation. He is best known as the co-founder of two biotechnology companies, Medarex Inc. and Genmab A/S, both of which develop drugs used in monoclonal antibody therapy. During his tenure as the founding CEO of Medarex, the company raised more than a billion dollars, entered into alliances with many other pharmaceutical companies, and spun off Genmab, which subsequently completed the largest biotechnology IPO in the history of European capital markets up to the time of the offering. He was an Ernst & Young Entrepreneur of the Year in 2005. He serves as a Trustee of Drew University, a Visitor of Ralston College, a member of the Board of Advisors of the Rutgers Business School, and formerly served as a Trustee of the Woodrow Wilson National Fellowship Foundation and of the University of Charleston. He is also a member of the editorial board of the journal mAbs. He was formerly the Chairman of the New Jersey Commission on Science and Technology, and has served on the boards of several companies, including Oxford Glycosciences, IDM-Pharma, and Mannkind. He continues to be a Director of Zymeworks Inc. He is in addition a Fellow of the Royal Society of Biology, the Royal Historical Society, and of the Burgon Society.
Before the 1921 destruction of Tulsa’s Greenwood District, Black residents had created a remarkable center of business and community life. The district included stores, professional offices, entertainment venues and homes owned by Black citizens. Understanding Greenwood means learning what was built—not only what was burned.
MORE →Shirley Chisholm, elected in 1968.
